Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
作者： Román Peréz-Soler , Leonard Saltz
关键词: Oncology 、 Cetuximab 、 Survival analysis 、 Epidermal growth factor receptor 、 Immunology 、 Gefitinib 、 Erlotinib 、 Surrogate endpoint 、 Internal medicine 、 Medicine 、 Rash 、 Adverse effect
摘要: The human epidermal growth factor receptor (HER1/EGFR) is dysregulated in many solid tumors, making it an attractive target for anticancer therapy. A number of agents that target this …
elsevier.com
sci-hub.se 参考文章(53)
R. Murillas, F. Larcher, C. J. Conti, M. Santos, A. Ullrich, J. L. Jorcano, Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. The EMBO Journal. ,vol. 14, pp. 5216- 5223 ,(1995) , 10.1002/J.1460-2075.1995.TB00206.X
Takanori Kanematsu, Seiji Yano, Hisanori Uehara, Yoshimi Bando, Saburo Sone, Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncology Research. ,vol. 13, pp. 289- 298 ,(2003) , 10.3727/096504003108748348
Lloyd E King, Ronald E Gates, Christa M Stoscheck, Lillian B Nanney, The EGF/TGFα Receptor in Skin Journal of Investigative Dermatology. ,vol. 94, pp. s164- s170 ,(1990) , 10.1111/1523-1747.EP12876141
Terry Magnuson, David W. Threadgill, John P. Sundberg, Laura A. Hansen, Stuart H. Yuspa, Margaret E. Hogan, Andrzej Dlugosz, Natalie Alexander, Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development American Journal of Pathology. ,vol. 150, pp. 1959- 1975 ,(1997)
J. Baselga, D. Pfister, M.R. Cooper, R. Cohen, B. Burtness, M. Bos, G. D’Andrea, A. Seidman, L. Norton, K. Gunnett, J. Falcey, V. Anderson, H. Waksal, J. Mendelsohn, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin Journal of Clinical Oncology. ,vol. 18, pp. 904- 914 ,(2000) , 10.1200/JCO.2000.18.4.904
Maria Sibilia, Alexander Fleischmann, Axel Behrens, Laura Stingl, Joseph Carroll, Fiona M. Watt, Joseph Schlessinger, Erwin F. Wagner, The EGF Receptor Provides an Essential Survival Signal for SOS-Dependent Skin Tumor Development Cell. ,vol. 102, pp. 211- 220 ,(2000) , 10.1016/S0092-8674(00)00026-X
Brian Higgins, Kenneth Kolinsky, Melissa Smith, Gordon Beck, Mohammad Rashed, Violeta Adames, Michael Linn, Eric Wheeldon, Laurent Gand, Herbert Birnboeck, Gerhard Hoffmann, Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anti-Cancer Drugs. ,vol. 15, pp. 503- 512 ,(2004) , 10.1097/01.CAD.0000127664.66472.60
Roy S. Herbst, Patricia M. LoRusso, Michele Purdom, Deborah Ward, Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management Clinical Lung Cancer. ,vol. 4, pp. 366- 369 ,(2003) , 10.3816/CLC.2003.N.016
Lloyd E. King, Ronald E. Gates, Christa M. Stoscheck, Lillian B. Nanney, Epidermal growth factor/transforming growth factor alpha receptors and psoriasis. Journal of Investigative Dermatology. ,vol. 95, ,(1990) , 10.1111/1523-1747.EP12505661
Jinny Park, Byeong-Bae Park, Se-Hoon Lee, Se Hoon Park, Kyung-Eun Lee, Soon Lee, Eunmi Nam, Joon Oh Park, Young-Hyuck Lim, Keunchil Park, None, P-620 Gefitinib (‘Iressa’, ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small-cell lung cancer (NSCLC) Lung Cancer. ,vol. 41, ,(2003) , 10.1016/S0169-5002(03)92587-6